【#长春高新回应儿童小阴茎专用药获批#：上市至少要三年】#儿童小阴茎专用药上市至少三年#27日， 长春高新股价开盘走低，一度跌超4%。截至发稿，长春高新报95.88元/股。对于股价走势，@中新经纬 以投资者身份致电长春高新证券部，一位工作人员回应称，"股价涨跌背后，没有特殊原因。"2月24 日，长春高新发布公告称，子公司金赛药业GenSci141软膏境内生产药品注册临床试验申请获得批准。 该药品用于改善因高促性腺激素性性腺功能减退症、5α-还原酶2缺乏症、雄激素合成减少的先天性肾上 腺皮质增生症、特发性原因导致的儿童小阴茎。对于GenSci141软膏的研发进展，上述工作人员回应 称，基于对药物研发的通常理解，一切顺利的情况下，从临床获批到上市的周期，至少也要三年。但每 一个试验阶段都存在不确定性，都会影响到后续药品上市的时间。 转自：贝壳财经 ...

来源：每经网 2月26日，长春高新股价继续收涨，周涨幅超12%。其子公司金赛药业GenSci141软膏临床试验申请获 批，这是全球首款针对儿童小阴茎的药物，但项目尚处早期。近两年，长春高新业绩承压，2025年净利 预计下滑超90%，正转型布局多领域。去年12月金赛药业子公司签订独家许可协议，不过相关款项2025 年度尚未确认，未能改善业绩。 ...

Core Viewpoint - Changchun High-tech's stock price surged by 11.4% over two trading days, closing at 98.50 yuan per share, with a total market value of 40.18 billion yuan [1] Group 1: Clinical Trial Approval - Changchun High-tech's subsidiary, GenSci, received approval from the National Medical Products Administration for clinical trials of GenSci141 ointment, aimed at treating conditions related to hypogonadism and congenital adrenal hyperplasia in children [3] - The announcement highlighted that drug treatment is the primary method for addressing penile size issues in boys, with no approved medications for this indication until now [3] Group 2: Financial Performance - The company projected a significant decline in net profit for 2025, estimating between 150 million to 220 million yuan, representing a year-on-year decrease of 91.48% to 94.19% [4] - The fourth quarter is expected to show a massive loss of 945 million to 1.015 billion yuan, with a year-on-year increase in losses of 358.74% to 392.72% [5] - The decline in profit is attributed to pricing adjustments in the growth hormone business, ongoing losses from its subsidiary, and high costs associated with new product development [5] Group 3: Market Competition and Future Prospects - The growth hormone market has become increasingly competitive, necessitating Changchun High-tech to seek new revenue growth points [6] - The potential of GenSci141 ointment to drive revenue remains uncertain as it is still in the clinical trial phase [6] - The company has a rich pipeline of products and is focusing on new products with high market potential, such as Jin Peixin and Meishiya, which have shown promising sales figures [7]

记者丨韩利明 编辑丨季媛媛 张伟贤 曾静娇 2月25日，长春高新（000661.SZ）以涨停收盘，报97.26元/股，收获2026年开年以来首个涨停；2月26日 公司股价持续上行，截至14：30左右，报100元/股，涨幅2.82%，总市值达408亿元，股价两日累计涨超 12%。 | | 100.00 +2.74 +2.82% | | | | | 広官同射 000661 | | --- | --- | --- | --- | --- | --- | --- | | SZSE CNY 14:33:33 交易中 | | | | | | 通融/ + | | 委比 | 80.74% 委差 | 3758 | Wind ESG评级 | BBB | | 详情 | | 卖五 | 100.05 | 122 | રેસ | 8.05% 120日 | | -3.22% | | 卖四 | 100.04 | 42 | 5日 | 13.52% 250日 | | 4.97% | | 卖三 | 100.03 | 130 | 20日 | 2.36% 52周高 | | 141.77 | | 卖二 | 100.02 | વેરુ | 60日 | 0 ...

近日，长春高新发布公告称，子公司金赛药业GenSci141软膏境内生产药品注册临床试验申请获得批准，该药品用于 改善因高促性腺激素性性腺功能减退症、5α-还原酶2缺乏症、雄激素合成减少的先天性肾上腺皮质增生症、特发性的 原因导致的儿童小阴茎。 （长春高新公告） ...

长春高新公告，子公司金赛药业收到国家药品监督管理局核准签发的《药物临床试验批准通知书》，金 赛药业GenSci141软膏境内生产药品注册临床试验申请获得批准。GenSci141软膏是金赛药业研发的一款 双氢睾酮软膏，属于化学药品2.2类、2.4类。 ...

尽管隆培生长激素的官方定价尚未公布，但市场对其讨论热度居高不下。参考全球定价，该产品在美国 的年治疗成本高达50万至60万元，而国内市场普遍预判，其本土年治疗费用将大幅低于这一水平。这种 兼顾品质与性价比的潜在优势，进一步放大了市场期待。 一旦这条路径走通，不仅能帮助维昇药业抢占高端市场先机，更有望推动整个生长激素赛道的发展逻辑 重构，这将是一个不同于以往的里程碑式转折。 近日，维昇药业核心产品隆培生长激素注射液（维臻高，Skytrofa）获批上市，用于治疗儿童生长激素 缺乏症（PGHD），是全球唯一优效于日制剂的长效生长激素。 自此，国内长效生长激素阵营已扩容至4款产品，呈现出鲜明的分化特征。其中，唯有隆培生长激素采 用天然分子结构，与人体自身分泌的生长激素氨基酸序列完全一致，而其余产品均为重组分子结构。 可以说，隆培生长激素的登场，既是维昇药业瞄准市场痛点的一次差异化布局，更是长效生长激素赛道 的一次突破性"社会实验"。 2月2日，维昇药业召开投资人交流会，与投资者展开深度交流，围绕这款产品的临床价值与未来商业化 路径，主动、清晰且坦诚地向市场传递公司的判断与战略思考。 唯一实现迭代性突破的产品，拥有独特 ...

Core Viewpoint - Changchun High-tech's 2025 performance forecast indicates a significant decline in key financial metrics, with net profit expected to drop by 91.48%-94.19% compared to 2024, reflecting ongoing challenges in the company's operations [1][2]. Financial Performance - The company anticipates a net profit attributable to shareholders of 150 million to 220 million yuan for 2025, a drastic decrease from 2.583 billion yuan in 2024 [1][2]. - The non-recurring net profit is projected to decline by 82.09%-84.56%, with basic earnings per share shrinking from 6.42 yuan to between 0.37 yuan and 0.55 yuan [1][2]. - For the first three quarters of 2024, the company reported a revenue of 9.807 billion yuan, down 5.60% year-on-year, and a net profit of 1.165 billion yuan, down 58.23% year-on-year, indicating worsening performance in the fourth quarter [2]. Business Challenges - The decline in performance is attributed to multiple pressures, including pricing adjustments in the growth hormone business following its inclusion in the medical insurance catalog, ongoing losses from subsidiary Baike Biology, and high costs associated with R&D and new product market cultivation [2][3]. - The growth hormone business, which is a key revenue driver, faces significant profit margin compression due to new pricing policies and increased competition from generic drug manufacturers [5][6]. Market Dynamics - The inclusion of long-acting growth hormone in the national medical insurance catalog is seen as a double-edged sword; while it expands patient access, it also necessitates price reductions that adversely affect profit margins [5][6]. - The competitive landscape has intensified, with the market no longer dominated by JinSai Pharmaceuticals, leading to increased pricing pressure and reduced profit contributions from the growth hormone segment [6][12]. Innovation and Strategic Initiatives - Despite short-term pressures, JinSai Pharmaceuticals is advancing its innovation and internationalization strategies, with multiple new product approvals and collaborations aimed at expanding market reach [3][8]. - The company has submitted an H-share listing application to the Hong Kong Stock Exchange, aiming to enhance financing channels and support its growth strategy [11]. - Significant R&D investments are being made, with R&D expenses reaching 1.733 billion yuan in the first three quarters of 2025, representing a 22.96% increase year-on-year [9][12]. Future Outlook - The successful commercialization of innovative products, such as JinBeiXin® and MeiShiYa®, which have been included in the medical insurance catalog, is expected to drive revenue growth and offset declines in traditional segments [9][12]. - The internationalization strategy, including partnerships and market expansion efforts, is anticipated to open new growth avenues and enhance the company's competitive position in the global market [11][12].

Core Viewpoint - Changchun High-tech announced that its subsidiary, Jinsai Pharmaceutical, has had its clinical trial application for the domestically produced injectable GenSci136 accepted by the National Medical Products Administration, marking a significant step in the development of a new treatment for myasthenia gravis [1] Group 1: Product Development - GenSci136 is a Class 1 biological product designed to treat generalized myasthenia gravis, featuring a novel drug structure and a dual-target mechanism of action [1] - The drug aims to provide better treatment options for patients with myasthenia gravis in China [1] Group 2: Business Impact - The progress of this application is expected to broaden the company's business structure and enhance its core competitiveness [1] - The clinical trial process, however, still carries uncertainties that could affect the timeline and outcomes [1]

Investment Rating - The report maintains a rating of "Buy" for the pharmaceutical and biotechnology sector [5]. Core Insights - The report emphasizes the continuous focus on investment opportunities related to AI in healthcare, driven by the growth of Tencent's AI applications and the need for data-driven solutions in medical settings [2][21]. - The investment logic centers around "data closed-loop" and "scene demand," highlighting AI's role as a core productivity driver in healthcare under the dual pressures of cost control and technological advancements [22]. - The report outlines a three-stage clinical value investment strategy, focusing on innovative drug chains and medical devices, with specific recommendations for companies in these sectors [3][27]. Summary by Sections Market Review - Last week, the A-share pharmaceutical and biotechnology index fell by 3.31%, underperforming the CSI 300 index by 3.39 percentage points and ranking 22nd among 31 sub-industries [1][15]. - The Hong Kong Hang Seng Medical Health Index also declined by 2.98%, lagging behind the Hang Seng Index by 4.69 percentage points [1][15]. R&D Progress - Recent developments include new drug applications from companies such as Hengrui Medicine and Innovent Biologics, with ongoing clinical trials for various products [30]. Key Companies and Valuation - The report provides a detailed earnings forecast and valuation table for key companies, recommending "Buy" for several firms including Innovent Biologics, WuXi AppTec, and Mindray Medical [4][27]. AI Healthcare Investment Focus - The report identifies several core areas for AI in healthcare, including AI drug development, medical imaging, chronic disease management, and surgical robotics, emphasizing the importance of proprietary data and business scenarios for competitive advantage [22][24]. Annual Investment Strategy - The report suggests that the investment focus should increasingly emphasize the clinical value of pharmaceuticals, with a positive outlook on innovative drug chains and high-end medical devices [3][26].